Patent details

EP2275110 Title: Cladribine regimen for treating Multiple Sclerosis

Basic Information

Publication number:
EP2275110
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP101826329
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
Cladribine regimen for treating Multiple Sclerosis
French Title of Invention:
Régime posologique de cladribine pour le traitement de la sclérose en plaques
German Title of Invention:
Cladribin Dosierschema zur Behandlung von multipler Sklerose
SPC Number:

Dates

Filing date:
20/12/2005
Grant date:
10/07/2013
EP Publication Date:
10/07/2013
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
19/01/2011
EP B1 Publication Date:
10/07/2013
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
20/12/2014
Expiration date:
20/12/2025
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
20/12/2005
 
 

Name:
Merck Serono SA
Address:
Centre Industriel, 1267 Coinsins, Vaud, Switzerland (CH)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
17/07/2013
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
Lopez-Bresnahan Maria
Address:
United States (US)

2

Name:
Munafo Alain
Address:
Switzerland (CH)

3

Name:
De Luca Giampiero
Address:
Switzerland (CH)

4

Name:
Ythier Arnoud
Address:
Switzerland (CH)

Priority

1

Priority Number:
638669 P
Priority Date:
22/12/2004
Priority Country:
United States (US)

2

Priority Number:
04106909
Priority Date:
22/12/2004
Priority Country:
European Patent Office (EPO) (EP)

Classification

Main IPC Class:
A61K 31/7076;
Filing date Document type Number of pages